drugset / Trial / NCT00295243
Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Participants will take GW572016 by mouth daily each cycle (cycles 28 days in length) and will be given Topotecan intravenously on Days 1, 8 and 15.
Timeline
- Start
- 2004-09
- Primary completion
- —
- Completion
- 2006-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lapatinib | Small molecule | — | Oral |
| Subject | Topotecan | Small molecule | — | Intravenous |